// App-Quantinova.ai

3 : Final results from a phase I trial and expansion cohorts of cabozantinib and nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) for metastatic genitourinary tumors.

Researchers

Presenter

  • Andrea B. Apolo

Principal Investigators

  • Scot Anthony Niglio

  • Rosa Maria Nadal

  • Lisa M. Cordes

  • Seth M. Steinberg

  • Rene Costello

  • Jane B Trepel

  • Sunmin Lee

  • Min-Jung Lee

  • Liang Cao

  • James L. Gulley

  • Donald P. Bottaro

  • Biren Saraiya

  • Sumanta K. Pal

  • David I. Quinn

  • Primo "Lucky" N. Lara

  • Howard L. Parnes

  • William L. Dahut

  • Amir Mortazavi

Medical Centers

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • Biostatistics and Data Management Section, CCR, National Cancer Institute, Bethesda, MD

  • Center for Cancer Research, NCI, NIH, Bethesda, MD

  • Gastrointestinal Malignancies Section, Center for Cancer Research, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • Center for Cancer Research, Division of Cancer Treatment and Diagnosis, Bethesda, MD

  • Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

  • Norris Cancer Hospital, Los Angeles, CA

  • University of California, San Francisco, CA

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

  • National Cancer Institute, Bethesda, MD

  • Arthur G. James Cancer Hospital, The Ohio State University Wexner Medical Center, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Clear cell renal carcinoma

  • Bladder Cancer

  • Renal cell carcinoma

  • Penile carcinoma

Biomarkers

  • Phosphatidylinositol Glycan, Class F

  • Circulating tumor cells

  • Epithelial Cell Adhesion Molecule

  • Kinase Insert Domain Receptor

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Cabozantinib

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02496208

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved